A Randomized, Open-label, Replicate, Crossover, 4-period Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-dose Combination 200/300 mg Tablets From Ardea Biosciences, Inc. (Test Drug) Versus Lesinurad, 200 mg Tablet From AstraZeneca (Comparator 1) Coadministered With Zyloric®, Allopurinol 300 mg Tablet From Aspen Pharma Industria Farmaceutica Ltda. (Comparator 2) in Healthy Female and Male Adult Subjects, Under Fasting Conditions.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Allopurinol/lesinurad (Primary) ; Allopurinol; Lesinurad
- Indications Gout
- Focus Pharmacokinetics
- Sponsors Ardea Biosciences
- 06 Nov 2018 Status changed from recruiting to completed.
- 07 Sep 2017 New trial record